• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在真实临床实践中,急性冠脉综合征患者队列的长期血脂目标的实现。

Achievement of long-term lipid targets in a cohort of patients with acute coronary syndrome in real-world clinical practice.

机构信息

Unidad de Lípidos y Riesgo Vascular, Servicio de Medicina Interna, Hospital Marqués de Valdecilla, Santander, Cantabria, Spain.

Servicio de Cardiología, Hospital Marqués de Valdecilla, Santander, Cantabria, Spain.

出版信息

Rev Clin Esp (Barc). 2023 Apr;223(4):223-230. doi: 10.1016/j.rceng.2023.02.011. Epub 2023 Mar 16.

DOI:10.1016/j.rceng.2023.02.011
PMID:36933696
Abstract

INTRODUCTION AND OBJECTIVES

According to the recent European epidemiological studies, the degree of lipid control in patients with very high vascular risk is suboptimal. This study analyzes the epidemiological characteristics, cardiovascular risk factors, lipid profile, recurrence, and degree of achievement of long-term lipid targets, according to the ESC/EAS Guidelines, in a cohort of patients with acute coronary syndrome (ACS) in a real-world clinical practice setting.

METHODS

This work is a retrospective cohort study of patients diagnosed with ACS admitted to the Coronary Unit of a tertiary hospital from January 1, 2012 to December 31, 2015 and followed-up on until March 2022.

RESULTS

A total of 826 patients were studied. During the follow-up period, greater prescribing of combined lipid-lowering therapy was observed, mainly high- and moderate-intensity statins and ezetimibe. At 24 months after the ACS, 33.6% of living patients had LDL levels <70 mg/dl and 9.3% had LDL levels <55 mg/dl. At the end of the follow-up (101 [88-111] months), the corresponding figures were 54.5% and 21.1%. Some 22.1% of patients had a recurrent coronary event and only 24.6% achieved an LDL level <55 mg/dl.

CONCLUSIONS

Achievement of the LDL targets recommended by the ESC/EAS guidelines is suboptimal in patients with ACS, both at two years and in the long-term (7-10 years), especially in patients with recurrent ACS.

摘要

简介和目的

根据最近的欧洲流行病学研究,极高血管风险患者的血脂控制程度不理想。本研究根据 ESC/EAS 指南,分析了在真实临床实践环境中急性冠状动脉综合征(ACS)患者队列的流行病学特征、心血管危险因素、血脂谱、复发情况以及长期血脂目标的达标程度。

方法

这是一项回顾性队列研究,纳入了 2012 年 1 月 1 日至 2015 年 12 月 31 日期间因 ACS 入住三级医院冠状动脉病房的患者,并随访至 2022 年 3 月。

结果

共纳入 826 例患者。在随访期间,观察到联合降脂治疗的处方率增加,主要是高强度和中强度他汀类药物和依折麦布。ACS 后 24 个月,33.6%的存活患者 LDL 水平<70mg/dl,9.3%的患者 LDL 水平<55mg/dl。在随访结束时(101[88-111]个月),相应的比例分别为 54.5%和 21.1%。约 22.1%的患者发生了复发性冠状动脉事件,只有 24.6%的患者 LDL 水平<55mg/dl。

结论

ACS 患者 LDL 目标的达标程度不理想,无论是在两年内还是在长期(7-10 年)内,尤其是在复发性 ACS 患者中。

相似文献

1
Achievement of long-term lipid targets in a cohort of patients with acute coronary syndrome in real-world clinical practice.在真实临床实践中,急性冠脉综合征患者队列的长期血脂目标的实现。
Rev Clin Esp (Barc). 2023 Apr;223(4):223-230. doi: 10.1016/j.rceng.2023.02.011. Epub 2023 Mar 16.
2
How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic.欧洲心脏病学会/欧洲动脉粥样硬化学会(ESC/EAS)和2013年美国心脏病学会/美国心脏协会(ACC/AHA)血脂异常治疗指南的效果如何?来自一家血脂诊所的经验教训。
Curr Med Res Opin. 2015 Feb;31(2):221-8. doi: 10.1185/03007995.2014.982751. Epub 2014 Nov 24.
3
Suboptimal achievement of low-density lipoprotein cholesterol targets in French patients with coronary heart disease. Contemporary data from the DYSIS II ACS/CHD study.法国冠心病患者低密度脂蛋白胆固醇目标未达最佳水平。来自DYSIS II ACS/CHD研究的当代数据。
Arch Cardiovasc Dis. 2017 Mar;110(3):167-178. doi: 10.1016/j.acvd.2016.11.004. Epub 2017 Feb 13.
4
The effect of the 2019 ESC/EAS dyslipidaemia guidelines on low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS EuroPath IV project.2019 ESC/EAS 血脂异常指南对急性冠状动脉综合征患者低密度脂蛋白胆固醇目标达标率的影响:ACS EuroPath IV 项目。
Vascul Pharmacol. 2023 Feb;148:107141. doi: 10.1016/j.vph.2023.107141. Epub 2023 Jan 7.
5
Prior adherence to recommended lipid control targets in patients admitted for acute coronary syndrome.急性冠状动脉综合征患者入院时推荐的血脂控制目标的先前依从情况。
Rev Esp Cardiol (Engl Ed). 2020 May;73(5):376-382. doi: 10.1016/j.rec.2019.06.014. Epub 2019 Nov 6.
6
Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project.降脂治疗和急性冠状动脉综合征患者的低密度脂蛋白胆固醇目标达标情况:ACS 患者路径项目。
Atheroscler Suppl. 2020 Dec;42:e49-e58. doi: 10.1016/j.atherosclerosissup.2021.01.009.
7
Impact of a virtual lipid clinic on lipid-lowering therapy, LDL cholesterol levels, and outcomes in patients with acute coronary syndrome.虚拟脂类诊所对急性冠脉综合征患者降脂治疗、LDL 胆固醇水平和结局的影响。
J Clin Lipidol. 2022 Sep-Oct;16(5):635-642. doi: 10.1016/j.jacl.2022.07.009. Epub 2022 Jul 28.
8
[The importance of intensive lipid-lowering therapy after acute coronary syndrome: changing the paradigm to improve the achievement of targets].[急性冠状动脉综合征后强化降脂治疗的重要性:改变范式以提高目标达成率]
G Ital Cardiol (Rome). 2022 Jul;23(7):553-561. doi: 10.1714/3831.38173.
9
Impact of the Spanish consensus for improving lipid control on patients admitted for an acute coronary syndrome.西班牙改善血脂控制共识对急性冠状动脉综合征住院患者的影响。
J Clin Lipidol. 2023 Nov-Dec;17(6):756-764. doi: 10.1016/j.jacl.2023.10.002. Epub 2023 Oct 5.
10
Prospective evaluation of lipid management following acute coronary syndrome in Saudi Arabia.沙特阿拉伯急性冠状动脉综合征患者血脂管理的前瞻性评估。
Saudi Med J. 2023 Jun;44(6):570-579. doi: 10.15537/smj.2023.44.6.20230023.

引用本文的文献

1
Residual cardiovascular risk, use of standard care treatments, and achievement of treatment goals in patients with cardiovascular disease.心血管疾病患者的残余心血管风险、标准治疗方法的使用及治疗目标的达成情况。
Int J Cardiol Cardiovasc Risk Prev. 2023 Jul 21;18:200198. doi: 10.1016/j.ijcrp.2023.200198. eCollection 2023 Sep.